Another anti-EGFR monoclonal (necitumumab) was recently approved in combination with cisplatin/gemcitabine chemotherapy as a first line treatment in advanced squamous subtype of NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.